ArticleRenal failure2025
Alpha-1-microglobulin profile in patients on maintenance hemodialysis and its removal by blood purification.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment of Restless Legs Syndrome in Dialysis Patients.Seminars in dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-1-microglobulin (A1M), metabolized in renal tubules, plays an important role as a potent antioxidant in human cells. The majority of A1M is present in the blood in free form and in a bound form with IgA dimers, with the free form thought to have antioxidant capacity. However, the dynamics of A1M in chronic kidney disease patients being susceptible to oxidative stress remain unclear. The present study aimed to determine the profile and changes in A1M resulting from blood purification in patients undergoing maintenance hemodialysis (HD) (including hemodiafiltration). Eighteen patients on stable maintenance HD were included in the study. For analysis, residual serum samples were collected from these patients during routine blood tests. A1M was measured using a latex agglutination immunoassay. The abundance of the free and bound forms of A1M was determined by native PAGE. The A1M concentration was 91.58 ± 26.34 mg/L, the percentage of free A1M was 72.62 ± 20.02%. The pre- and postdialysis mean concentration of free A1M were 68.74 ± 29.78 and 52.13 ± 22.48 mg/L, respectively. The mean reduction rate in free A1M after blood purification treatment was 20.49 ± 20.91%, showing the significant difference between pre- and postdialysis concentrations. The predialysis mean concentration of protein-bound A1M was 22.85 ± 15.16 mg/L, with a postdialysis concentration of 24.73 ± 12.82 mg/L. The novel finding of this study is that A1M in patients on maintenance HD exists pre-dominantly in the free form and can be effectively removed by hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.